Literature DB >> 10353969

The cost of medical care for patients with cystic fibrosis in a health maintenance organization.

T A Lieu1, G T Ray, G Farmer, G F Shay.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among white individuals worldwide. Previous estimates of the costs of medical care have been based on expert opinion rather than observed costs. Accurate cost estimates are needed to enable evaluation of the cost-effectiveness of new interventions and prenatal genetic screening recommendations.
OBJECTIVE: To evaluate the cost of medical care for patients (N = 136) served by a health maintenance organization with a CF center.
METHODS: Retrospective analysis of data from computerized cost databases and the Cystic Fibrosis Foundation annual survey. Severity of disease was classified based on the percent predicted forced expiratory volume at 1 second.
RESULTS: The annual cost of medical care in 1996 averaged $13 300 and ranged from $6200 among patients with mild disease to $43 300 among patients with severe disease. Of total costs, 47% were from hospitalization, 18% were from DNase (Pulmozyme), 12% were from clinic visits, and 10% were from outpatient antibiotics. When the observed costs were used to estimate the costs of medical care for the entire population of CF patients in the United States, these costs were estimated to be $314 million per year in 1996 dollars.
CONCLUSIONS: We conclude that the cost of medical care for CF varies greatly with severity but is substantial even among patients with mild disease. These findings underscore the need for strategies to ensure good health insurance coverage and high quality care for all individuals with this condition.

Entities:  

Mesh:

Year:  1999        PMID: 10353969     DOI: 10.1542/peds.103.6.e72

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  31 in total

Review 1.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

2.  Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.

Authors:  Lisa A Carmody; Jiangchao Zhao; Patrick D Schloss; Joseph F Petrosino; Susan Murray; Vincent B Young; Jun Z Li; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2013-06

3.  Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.

Authors:  Donald R VanDevanter; David J Pasta; Michael W Konstan
Journal:  J Cyst Fibros       Date:  2015-03-06       Impact factor: 5.482

4.  Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.

Authors:  Abaigeal D Jackson; Andrew L Jackson; Godfrey Fletcher; Gerardine Doyle; Mary Harrington; Shijun Zhou; Fiona Cullinane; Charles Gallagher; Edward McKone
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

5.  Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

Authors:  D R Vandevanter; A Yegin; W J Morgan; S J Millar; D J Pasta; M W Konstan
Journal:  J Cyst Fibros       Date:  2011-07-30       Impact factor: 5.482

6.  Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Authors:  Don B Sanders; George M Solomon; Valeria V Beckett; Natalie E West; Cori L Daines; Sonya L Heltshe; Donald R VanDevanter; Jonathan E Spahr; Ronald L Gibson; Jerry A Nick; Bruce C Marshall; Patrick A Flume; Christopher H Goss
Journal:  J Cyst Fibros       Date:  2017-04-29       Impact factor: 5.482

Review 7.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 8.  Background and Epidemiology.

Authors:  Don B Sanders; Aliza K Fink
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

9.  Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

Authors:  D R VanDevanter; P A Flume; N Morris; M W Konstan
Journal:  J Cyst Fibros       Date:  2016-04-29       Impact factor: 5.482

10.  [Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results].

Authors:  Daniela Eidt; Thomas Mittendorf; Thomas O F Wagner; Andreas Reimann; J-Matthias Graf von der Schulenburg
Journal:  Med Klin (Munich)       Date:  2009-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.